{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:12:47Z","timestamp":1794651167249,"version":"4.9.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-68973-5","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:23:31Z","timestamp":1770481411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Urinary clusterin as a biomarker of human kidney disease progression and response to the endothelin receptor antagonist atrasentan: An exploratory analysis from the SONAR trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9136-8454","authenticated-orcid":false,"given":"Wenjun","family":"Ju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viji","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Vart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. David","family":"Smeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Hudkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3983-5136","authenticated-orcid":false,"given":"Erik","family":"Moedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Larkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2087-5691","authenticated-orcid":false,"given":"Paul","family":"Perco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2923-827X","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Burdet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerby","family":"Shedden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5546-6812","authenticated-orcid":false,"given":"Michael","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2443-6638","authenticated-orcid":false,"given":"Edmond","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalita","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3711-2984","authenticated-orcid":false,"given":"Markus","family":"Bitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3152-5670","authenticated-orcid":false,"given":"Mark","family":"Ibberson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Duffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6210-3142","authenticated-orcid":false,"given":"Maria F.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1859-1772","authenticated-orcid":false,"given":"Charles E.","family":"Alpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kretzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"68973_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/ki.2014.143","volume":"86","author":"DE Kohan","year":"2014","unstructured":"Kohan, D. E. & Barton, M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 86, 896\u2013904 (2014).","journal-title":"Kidney Int."},{"key":"68973_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrneph.2012.19","volume":"8","author":"I Helal","year":"2012","unstructured":"Helal, I., Fick-Brosnahan, G. M., Reed-Gitomer, B. & Schrier, R. W. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat. Rev. Nephrol. 8, 293\u2013300 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"68973_CR3","doi-asserted-by":"publisher","first-page":"872918","DOI":"10.3389\/fendo.2022.872918","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang, Y. & Xu, G. Update on Pathogenesis of Glomerular Hyperfiltration in Early Diabetic Kidney Disease. Front. Endocrinol. 13, 872918 (2022).","journal-title":"Front. Endocrinol."},{"key":"68973_CR4","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-D\u00edaz, I. et al. Endothelin Receptor Antagonists in Kidney Disease. Int. J. Mol. Sci. 24, https:\/\/doi.org\/10.3390\/ijms24043427 (2023).","DOI":"10.3390\/ijms24043427"},{"key":"68973_CR5","doi-asserted-by":"publisher","first-page":"F1295","DOI":"10.1152\/ajprenal.00498.2019","volume":"318","author":"KL Hudkins","year":"2020","unstructured":"Hudkins, K. L., Wietecha, T. A., Steegh, F. & Alpers, C. E. Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy. Am. J. Physiol. Renal Physiol. 318, F1295\u2013f1305 (2020).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"68973_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/13543784.2017.1325872","volume":"26","author":"J Egido","year":"2017","unstructured":"Egido, J. et al. Atrasentan for the treatment of diabetic nephropathy. Expert Opin. Investig. Drugs 26, 741\u2013750 (2017).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"68973_CR7","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.lfs.2012.01.011","volume":"91","author":"DL Andress","year":"2012","unstructured":"Andress, D. L. et al. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci. 91, 739\u2013742 (2012).","journal-title":"Life Sci."},{"key":"68973_CR8","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1681\/ASN.2013080830","volume":"25","author":"D de Zeeuw","year":"2014","unstructured":"de Zeeuw, D. et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 25, 1083\u20131093 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"68973_CR9","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","volume":"393","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink, H. J. L. et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393, 1937\u20131947 (2019).","journal-title":"Lancet"},{"key":"68973_CR10","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.2215\/CJN.07340521","volume":"16","author":"SW Waijer","year":"2021","unstructured":"Waijer, S. W. et al. The effect of atrasentan on kidney and heart failure outcomes by baseline Albuminuria and kidney function: a post Hoc analysis of the SONAR randomized trial. Clin. J. Am. Soc. Nephrol. 16, 1824\u20131832 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"68973_CR11","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/cpt.2143","volume":"109","author":"JV Koomen","year":"2021","unstructured":"Koomen, J. V. et al. Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clin. Pharmacol. Ther. 109, 1631\u20131638 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"68973_CR12","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/dom.13245","volume":"20","author":"HJL Heerspink","year":"2018","unstructured":"Heerspink, H. J. L. et al. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes. Metab. 20, 1369\u20131376 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"68973_CR13","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.kint.2023.07.007","volume":"104","author":"T Sen","year":"2023","unstructured":"Sen, T. et al. Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes. Kidney Int. 104, 828\u2013839 (2023).","journal-title":"Kidney Int."},{"key":"68973_CR14","first-page":"565","volume":"103","author":"LH Mariani","year":"2023","unstructured":"Mariani, L. H. et al. Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis. Kidney In. 103, 565\u2013579 (2023).","journal-title":"Kidney In."},{"key":"68973_CR15","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.2337\/db22-0169","volume":"71","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Multi-Scalar data integration links glomerular angiopoietin-tie signaling pathway activation with progression of diabetic kidney Disease. Diabetes 71, 2664\u20132676 (2022).","journal-title":"Diabetes"},{"key":"68973_CR16","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.2337\/dc21-2204","volume":"45","author":"CP Limonte","year":"2022","unstructured":"Limonte, C. P. et al. Urinary proteomics identifies cathepsin D as a biomarker of rapid eGFR decline in type 1 diabetes. Diabetes Care 45, 1416\u20131427 (2022).","journal-title":"Diabetes Care"},{"key":"68973_CR17","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1101\/gr.155697.113","volume":"23","author":"W Ju","year":"2013","unstructured":"Ju, W. et al. Defining cell-type specificity at the transcriptional level in human disease. Genome Res. 23, 1862\u20131873 (2013).","journal-title":"Genome Res."},{"key":"68973_CR18","doi-asserted-by":"publisher","first-page":"316ra193","DOI":"10.1126\/scitranslmed.aac7071","volume":"7","author":"W Ju","year":"2015","unstructured":"Ju, W. et al. Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci. Transl. Med. 7, 316ra193 (2015).","journal-title":"Sci. Transl. Med."},{"key":"68973_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10157-006-0421-z","volume":"10","author":"Y Yasuda","year":"2006","unstructured":"Yasuda, Y., Cohen, C. D., Henger, A. & Kretzler, M. Gene expression profiling analysis in nephrology: towards molecular definition of renal disease. Clin. Exp. Nephrol. 10, 91\u201398 (2006).","journal-title":"Clin. Exp. Nephrol."},{"key":"68973_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ki.2012.428","volume":"83","author":"CA Gadegbeku","year":"2013","unstructured":"Gadegbeku, C. A. et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int. 83, 749\u2013756 (2013).","journal-title":"Kidney Int."},{"key":"68973_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1053\/j.ajkd.2021.10.004","volume":"79","author":"JB Hodgin","year":"2022","unstructured":"Hodgin, J. B. et al. Quantification of glomerular structural lesions: associations with clinical outcomes and transcriptomic profiles in nephrotic syndrome. Am. J. Kidney Dis. 79, 807\u2013819 (2022).","journal-title":"Am. J. Kidney Dis."},{"key":"68973_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41586-023-05769-3","volume":"619","author":"BB Lake","year":"2023","unstructured":"Lake, B. B. et al. An atlas of healthy and injured cell states and niches in the human kidney. Nature 619, 585\u2013594 (2023).","journal-title":"Nature"},{"key":"68973_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/ng.3259","volume":"47","author":"CS Greene","year":"2015","unstructured":"Greene, C. S. et al. Understanding multicellular function and disease with human tissue-specific networks. Nat. Genet. 47, 569\u2013576 (2015).","journal-title":"Nat. Genet."},{"key":"68973_CR24","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1292\/jvms.18-0205","volume":"80","author":"JW Park","year":"2018","unstructured":"Park, J. W. et al. Clusterin is highly expressed in tubular complexes during spontaneous pancreatitis of spontaneous hypertensive rats. J. Vet. Med. Sci. 80, 1553\u20131557 (2018).","journal-title":"J. Vet. Med. Sci."},{"key":"68973_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11154-013-9275-3","volume":"15","author":"S Park","year":"2014","unstructured":"Park, S., Mathis, K. W. & Lee, I. K. The physiological roles of apolipoprotein J\/clusterin in metabolic and cardiovascular diseases. Rev. Endocr. Metab. Disord. 15, 45\u201353 (2014).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"68973_CR26","doi-asserted-by":"publisher","first-page":"e103351","DOI":"10.1371\/journal.pone.0103351","volume":"9","author":"JC Won","year":"2014","unstructured":"Won, J. C. et al. Plasma clusterin (ApoJ) levels are associated with adiposity and systemic inflammation. PLoS ONE 9, e103351 (2014).","journal-title":"PLoS ONE"},{"key":"68973_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/cen.13360","volume":"87","author":"SS Kim","year":"2017","unstructured":"Kim, S. S. et al. Urine clusterin\/apolipoprotein J is linked to tubular damage and renal outcomes in patients with type 2 diabetes mellitus. Clin. Endocrinol. 87, 156\u2013164 (2017).","journal-title":"Clin. Endocrinol."},{"key":"68973_CR28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/imcb.12405","volume":"99","author":"X Weng","year":"2021","unstructured":"Weng, X. et al. Clusterin regulates macrophage expansion, polarization and phagocytic activity in response to inflammation in the kidneys. Immunol. Cell Biol. 99, 274\u2013287 (2021).","journal-title":"Immunol. Cell Biol."},{"key":"68973_CR29","doi-asserted-by":"publisher","first-page":"F703","DOI":"10.1152\/ajprenal.00060.2001","volume":"282","author":"RA Girton","year":"2002","unstructured":"Girton, R. A., Sundin, D. P. & Rosenberg, M. E. Clusterin protects renal tubular epithelial cells from gentamicin-mediated cytotoxicity. Am. J. Physiol. Renal Physiol. 282, F703\u2013F709 (2002).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"68973_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52306-5","volume":"15","author":"NA Gujarati","year":"2024","unstructured":"Gujarati, N. A. et al. Podocyte-specific KLF6 primes proximal tubule CaMK1D signaling to attenuate diabetic kidney disease. Nat. Commun. 15, 8038 (2024).","journal-title":"Nat. Commun."},{"key":"68973_CR31","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/bcp.12282","volume":"77","author":"L van Meer","year":"2014","unstructured":"van Meer, L., Moerland, M., Cohen, A. F. & Burggraaf, J. Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development. Br. J. Clin. Pharmacol. 77, 947\u2013957 (2014).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"68973_CR32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/1357-2725(95)00027-M","volume":"27","author":"ME Rosenberg","year":"1995","unstructured":"Rosenberg, M. E. & Silkensen, J. Clusterin: Physiologic and pathophysiologic considerations. Int. J. Biochem. Cell Biol. 27, 633\u2013645 (1995).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"68973_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/toxsci\/kft330","volume":"138","author":"K Vlasakova","year":"2014","unstructured":"Vlasakova, K. et al. Evaluation of the relative performance of 12 urinary biomarkers for renal safety across 22 rat sensitivity and specificity studies. Toxicol. Sci. 138, 3\u201320 (2014).","journal-title":"Toxicol. Sci."},{"key":"68973_CR34","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1177\/0192623312444765","volume":"40","author":"P Vinken","year":"2012","unstructured":"Vinken, P. et al. Tissue Kim-1 and urinary clusterin as early indicators of cisplatin-induced acute kidney injury in rats. Toxicol. Pathol. 40, 1049\u20131062 (2012).","journal-title":"Toxicol. Pathol."},{"key":"68973_CR35","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.euf.2018.10.017","volume":"6","author":"BR Lane","year":"2020","unstructured":"Lane, B. R. et al. Evaluation of urinary renal biomarkers for early prediction of acute kidney injury following partial nephrectomy: a feasibility study. Eur. Urol Focus 6, 1240\u20131247 (2020).","journal-title":"Eur. Urol Focus"},{"key":"68973_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12882-017-0532-7","volume":"18","author":"F Mohamed","year":"2017","unstructured":"Mohamed, F. et al. Nephrotoxicity-induced proteinuria increases biomarker diagnostic thresholds in acute kidney injury. BMC Nephrol. 18, 122 (2017).","journal-title":"BMC Nephrol."},{"key":"68973_CR37","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2174\/1389200220666190711114504","volume":"20","author":"Y Da","year":"2019","unstructured":"Da, Y. et al. Serial quantification of urinary protein biomarkers to predict drug-induced acute kidney injury. Curr. Drug Metab. 20, 656\u2013664 (2019).","journal-title":"Curr. Drug Metab."},{"key":"68973_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nbt.1622","volume":"28","author":"F Dieterle","year":"2010","unstructured":"Dieterle, F. et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat. Biotechnol. 28, 463\u2013469 (2010).","journal-title":"Nat. Biotechnol."},{"key":"68973_CR39","first-page":"283","volume":"44","author":"T Voshaar","year":"1990","unstructured":"Voshaar, T., Schweisfurth, H., Schottes, C., Prinsen, J. & Koch, H. P. Serum theophylline concentrations in patients with chronic obstructive lung diseases: a comparison of 2 methods]. Pneumologie 44, 283\u2013284 (1990).","journal-title":"Pneumologie"},{"key":"68973_CR40","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1210\/en.2006-0291","volume":"147","author":"MN Raymond","year":"2006","unstructured":"Raymond, M. N., Bole-Feysot, C., Banno, Y., Tanfin, Z. & Robin, P. Endothelin-1 inhibits apoptosis through a sphingosine kinase 1-dependent mechanism in uterine leiomyoma ELT3 cells. Endocrinology 147, 5873\u20135882 (2006).","journal-title":"Endocrinology"},{"key":"68973_CR41","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1161\/01.HYP.30.5.1198","volume":"30","author":"M Shichiri","year":"1997","unstructured":"Shichiri, M., Kato, H., Marumo, F. & Hirata, Y. Endothelin-1 as an autocrine\/paracrine apoptosis survival factor for endothelial cells. Hypertension 30, 1198\u20131203 (1997).","journal-title":"Hypertension"},{"key":"68973_CR42","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/ki.1992.244","volume":"41","author":"R Vanholder","year":"1992","unstructured":"Vanholder, R., Hoefliger, N., De Smet, R. & Ringoir, S. Extraction of protein bound ligands from azotemic sera: comparison of 12 deproteinization methods. Kidney Int. 41, 1707\u20131712 (1992).","journal-title":"Kidney Int."},{"key":"68973_CR43","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10735-008-9201-2","volume":"39","author":"M Tuncdemir","year":"2008","unstructured":"Tuncdemir, M. & Ozturk, M. The effects of ACE inhibitor and angiotensin receptor blocker on clusterin and apoptosis in the kidney tissue of streptozotocin-diabetic rats. J. Mol. Histol. 39, 605\u2013616 (2008).","journal-title":"J. Mol. Histol."},{"key":"68973_CR44","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcp.22836","volume":"227","author":"N Kim","year":"2012","unstructured":"Kim, N. et al. Human nuclear clusterin mediates apoptosis by interacting with Bcl-XL through C-terminal coiled coil domain. J. Cell Physiol. 227, 1157\u20131167 (2012).","journal-title":"J. Cell Physiol."},{"key":"68973_CR45","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/sj.ki.5002563","volume":"73","author":"O Takase","year":"2008","unstructured":"Takase, O. et al. Inhibition of NF-kappaB-dependent Bcl-xL expression by clusterin promotes albumin-induced tubular cell apoptosis. Kidney Int. 73, 567\u2013577 (2008).","journal-title":"Kidney Int."},{"key":"68973_CR46","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1073\/pnas.0307159101","volume":"101","author":"RV Shohet","year":"2004","unstructured":"Shohet, R. V. et al. Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 101, 2088\u20132093 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68973_CR47","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00005344-200000002-00004","volume":"35","author":"FS Zollmann","year":"2000","unstructured":"Zollmann, F. S. & Paul, M. Transgenic models for the study of endothelin function in the cardiovascular system. J Cardiovasc. Pharmacol. 35, S13\u2013S16 (2000).","journal-title":"J Cardiovasc. Pharmacol."},{"key":"68973_CR48","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1161\/01.CIR.84.4.1457","volume":"84","author":"T Masaki","year":"1991","unstructured":"Masaki, T., Kimura, S., Yanagisawa, M. & Goto, K. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circulation 84, 1457\u20131468 (1991).","journal-title":"Circulation"},{"key":"68973_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1358863X9700200106","volume":"2","author":"RJ Parris","year":"1997","unstructured":"Parris, R. J. & Webb, D. J. The endothelin system in cardiovascular physiology and pathophysiology. Vasc. Med. 2, 31\u201343 (1997).","journal-title":"Vasc. Med."},{"key":"68973_CR50","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jacl.2016.11.009","volume":"11","author":"L Koller","year":"2017","unstructured":"Koller, L. et al. Clusterin\/apolipoprotein J is independently associated with survival in patients with chronic heart failure. J. Clin. Lipidol. 11, 178\u2013184 (2017).","journal-title":"J. Clin. Lipidol."},{"key":"68973_CR51","doi-asserted-by":"publisher","first-page":"466","DOI":"10.2337\/dc18-0870","volume":"42","author":"D Bradley","year":"2019","unstructured":"Bradley, D. et al. Clusterin impairs hepatic insulin sensitivity and adipocyte clusterin associates with cardiometabolic risk. Diabetes Care 42, 466\u2013475 (2019).","journal-title":"Diabetes Care"},{"key":"68973_CR52","doi-asserted-by":"publisher","first-page":"612496","DOI":"10.3389\/fimmu.2021.612496","volume":"12","author":"J Wittwer","year":"2021","unstructured":"Wittwer, J. & Bradley, D. Clusterin and Its Role in Insulin Resistance and the Cardiometabolic Syndrome. Front. Immunol. 12, 612496 (2021).","journal-title":"Front. Immunol."},{"key":"68973_CR53","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1042\/bj1330709","volume":"133","author":"AJ Barrett","year":"1973","unstructured":"Barrett, A. J. & Starkey, P. M. The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem. J. 133, 709\u2013724 (1973).","journal-title":"Biochem. J."},{"key":"68973_CR54","doi-asserted-by":"publisher","first-page":"e133267","DOI":"10.1172\/jci.insight.133267","volume":"5","author":"R Menon","year":"2020","unstructured":"Menon, R. et al. Single cell transcriptomics identifies focal segmental glomerulosclerosis remission endothelial biomarker. JCI Insight 5, e133267 (2020).","journal-title":"JCI Insight"},{"key":"68973_CR55","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1172\/JCI105107","volume":"43","author":"GR Joachim","year":"1964","unstructured":"Joachim, G. R., Cameron, J. S., Schwartz, M. & Becker, E. L. Selectivity of protein excretion in patients with the nephrotic syndrome. J. Clin. Invest. 43, 2332\u20132346 (1964).","journal-title":"J. Clin. Invest."},{"key":"68973_CR56","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1681\/ASN.2006080886","volume":"18","author":"G Zhang","year":"2007","unstructured":"Zhang, G. et al. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. J. Am. Soc. Nephrol. 18, 846\u2013859 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"68973_CR57","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1053\/j.ajkd.2024.01.520","volume":"84","author":"M de Cos","year":"2024","unstructured":"de Cos, M. et al. Urinary plasminogen as a marker of disease progression in human glomerular disease. Am. J. Kidney Dis. 84, 205\u2013214 (2024).","journal-title":"Am. J. Kidney Dis."},{"key":"68973_CR58","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 401, 1584\u20131594 (2023).","journal-title":"Lancet"},{"key":"68973_CR59","doi-asserted-by":"publisher","first-page":"S279","DOI":"10.1016\/j.ekir.2023.02.630","volume":"8","author":"H Lambers Heerspink","year":"2023","unstructured":"Lambers Heerspink, H. et al. Wcn23-1085 A Phase 3, Randomized, double-blind, placebo-controlled study of atrasentan in patients with Iga nephropaty- the align study. Kidney Int. Rep. 8, S279\u2013S280 (2023).","journal-title":"Kidney Int. Rep."},{"key":"68973_CR60","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","volume":"402","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet 402, 2004\u20132017 (2023).","journal-title":"Lancet"},{"key":"68973_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14755-5","volume":"7","author":"J Candia","year":"2017","unstructured":"Candia, J. et al. Assessment of variability in the SOMAscan assay. Sci. Rep. 7, 14248 (2017).","journal-title":"Sci. Rep."},{"key":"68973_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26640-w","volume":"8","author":"CH Kim","year":"2018","unstructured":"Kim, C. H. et al. Stability and reproducibility of proteomic profiles measured with an aptamer-based platform. Sci. Rep. 8, 8382 (2018).","journal-title":"Sci. Rep."},{"key":"68973_CR63","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"68973_CR64","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"68973_CR65","doi-asserted-by":"publisher","first-page":"D745","DOI":"10.1093\/nar\/gky1113","volume":"47","author":"F Cunningham","year":"2019","unstructured":"Cunningham, F. et al. Ensembl 2019. Nucleic Acids Res. 47, D745\u2013D751 (2019).","journal-title":"Nucleic Acids Res."},{"key":"68973_CR66","doi-asserted-by":"publisher","first-page":"D477","DOI":"10.1093\/nar\/gkx1019","volume":"46","author":"AM Altenhoff","year":"2018","unstructured":"Altenhoff, A. M. et al. The OMA orthology database in 2018: retrieving evolutionary relationships among all domains of life through richer web and programmatic interfaces. Nucleic Acids Res. 46, D477\u2013D485 (2018).","journal-title":"Nucleic Acids Res."},{"key":"68973_CR67","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2337\/db08-1328","volume":"58","author":"CC Berthier","year":"2009","unstructured":"Berthier, C. C. et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58, 469\u2013477 (2009).","journal-title":"Diabetes"},{"key":"68973_CR68","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kramer","year":"2014","unstructured":"Kramer, A., Green, J., Pollard, J. Jr. & Tugendreich, S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 523\u2013530 (2014).","journal-title":"Bioinformatics"},{"key":"68973_CR69","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1038\/nn.4353","volume":"19","author":"A Krishnan","year":"2016","unstructured":"Krishnan, A. et al. Genome-wide prediction and functional characterization of the genetic basis of autism spectrum disorder. Nat. Neurosci. 19, 1454\u20131462 (2016).","journal-title":"Nat. Neurosci."},{"key":"68973_CR70","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"68973_CR71","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 (2021).","journal-title":"Cell"},{"key":"68973_CR72","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888\u20131902 (2019).","journal-title":"Cell"},{"key":"68973_CR73","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"68973_CR74","doi-asserted-by":"publisher","DOI":"10.1093\/bioadv\/vbac016","volume":"2","author":"IMP Badia","year":"2022","unstructured":"Badia, I. M. P. et al. decoupleR: ensemble of computational methods to infer biological activities from omics data. Bioinform. Adv. 2, vbac016 (2022).","journal-title":"Bioinform. Adv."},{"key":"68973_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35519-4","volume":"13","author":"AE Murphy","year":"2022","unstructured":"Murphy, A. E. & Skene, N. G. A balanced measure shows superior performance of pseudobulk methods in single-cell RNA-sequencing analysis. Nat. Commun. 13, 7851 (2022).","journal-title":"Nat. Commun."},{"key":"68973_CR76","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0197-2456(00)00104-5","volume":"21","author":"FY Hsieh","year":"2000","unstructured":"Hsieh, F. Y. & Lavori, P. W. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin. Trials 21, 552\u2013560 (2000).","journal-title":"Control Clin. Trials"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68973-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:04:31Z","timestamp":1773677071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68973-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68973"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68973-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.K. reports grants and contracts through the University of Michigan unrelated of this work from Chan Zuckerberg Initiative, AstraZeneca, NovoNordisk, Eli Lilly, Boehringer-Ingelheim, European Union Innovative Medicine Initiative, Certa Therapeutics, RenalytixAI, Regeneron, Novo Nordisk, Sanofi, Dimerix, Travere and Vera Therapeutics. Also outside of this work, M.K. has received consulting fees through the University of Michigan from NovoNordisk, Alexion, Novartis, Roche Diagnostics and Vera Therapeutics. W.J., V.N., and M.K. hold a patent PCT\/EP2014\/073413 \u201cBiomarkers and methods for progression prediction for chronic kidney disease\u201d licensed. P.P. is an employee at Delta4 GmbH. Unrelated to this work, W.J. received consultancy fees from Travere Therapeutics. M.F.G. has received financial and non-financial (in kind) support from Boehringer Ingelheim Pharma GmbH, JDRF International, Eli Lilly, AbbVie, Sanofi-Aventis, Astellas, Novo Nordisk A\/S, Bayer AG, within EU grant H2020-JTI-lMl2-2015-05 (Grant agreement number 115974 - BEAt-DKD): She has also received financial and in kind support from Novo Nordisk, Pfizer, Follicum, Coegin Pharma, Abcentra, Probi, Johnson & Johnson, within a project funded by the Swedish Foundation for Strategic Research on precision medicine in diabetes (LUDC-IRC #15-0067). MFG has received personal consultancy fees from Lilly and Tribune Therapeutics AB. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2482"}}